Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 692.00K | 21.10M | 5.49M | 14.18M | 28.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 692.00K | 21.10M | 5.49M | 14.18M | 28.87M |
| Cost of Revenue | 17.48M | 12.86M | -43.32M | 18.77M | 15.78M |
| Gross Profit | -16.79M | 8.24M | 48.81M | -4.59M | 13.09M |
| SG&A Expenses | 9.75M | 9.23M | 8.76M | 7.60M | 9.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.23M | 22.10M | 20.27M | 26.37M | 25.13M |
| Operating Income | -26.54M | -996.00K | -14.78M | -12.19M | 3.74M |
| Income Before Tax | -31.78M | -1.04M | -15.53M | -12.77M | 3.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.78M | -1.04M | -15.53M | -12.77M | 3.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.78M | -1.04M | -15.53M | -12.77M | 3.25M |
| EBIT | -26.54M | -996.00K | -14.78M | -12.19M | 3.74M |
| EBITDA | -26.44M | -886.00K | -14.66M | -12.04M | 3.91M |
| EPS Basic | -0.07 | 0.00 | -0.04 | -0.04 | 0.01 |
| Normalized Basic EPS | -0.04 | 0.00 | -0.03 | -0.02 | 0.01 |
| EPS Diluted | -0.07 | 0.00 | -0.04 | -0.04 | 0.01 |
| Normalized Diluted EPS | -0.04 | 0.00 | -0.03 | -0.02 | 0.01 |
| Average Basic Shares Outstanding | 437.65M | 400.24M | 363.43M | 363.40M | 363.29M |
| Average Diluted Shares Outstanding | 437.65M | 400.24M | 363.43M | 363.40M | 363.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |